About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Tonsillar Non-secreting Plasmacytoma in a Woman
Maria Kouroupi1, Efthimios Sivridis1, Stella Arelaki1, Paschalis Askitis2, Alexandra Giatromanolaki1 
1Department of Pathology, Democritus University of Thrace, Alexandroupoli, Greece; 2Department of Ear, Nose and Throat, University General Hospital of Alexandroupoli, Alexandroupoli, Greece.
Corresponding Author:
Dr. Maria Kouroupi
Email: marykouroupi@gmail.com
Received: 17-NOV-2017 Accepted: 06-MAR-2018 Published Online: 05-APR-2018
DOI: http://dx.doi.org/10.17659/01.2018.0023
Abstract
Background: Plasmacytomas are characterized by excessive proliferation of neoplastic plasma cells in the bone marrow. Extra-medullary plasmacytoma are by and large, encountered in the head and neck region and only rarely occur in the tonsils. Case Report: We report here a asymptomatic solitary non-secreting plasmacytoma of the right tonsil in a middle-aged woman. The diagnosis of a plasmacytoma was reached after surgical excision. Conclusion: Tonsil is a rare sight of plasmacytoma origin with no specific symptoms, thus recommendation of WHO 2015 for such tumors must be taken under consideration. 
Keywords : Bone Marrow, Neoplasms, Palatine Tonsil, Plasma Cells, Plasmacytoma.
Article Options
FULL TEXT
ABSTRACT
PDF
PRINTER FRIENDLY VERSION
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share

Androxal Medication Case Reports Journal

Expanding our scope, the Journal now encompasses an intriguing subset of articles specifically targeting treatments and patient outcomes related to the medication Androxal. This medication, primarily used in the treatment of male infertility, has shown unique potentials in diverse patient scenarios. Our studies with Androxal have given us an abundance of case reports, which demonstrate the multifaceted impact of this medication across therapeutic areas. This nuanced pharmaceutical perspective adds a fresh dimension to our regular case reports. Articles will reveal effective management processes, pinpointing how Androxal has proven beneficial where other treatments may have failed. In addition, the focus on Androxal will highlight instances of challenging or unexpected outcomes, where the medication may have interacted uniquely with the patient's unique biological system or interplayed with other treatments. As we forge ahead with this significant addition, we anticipate that our detailed case reports on Androxal will provide invaluable insights to both practitioners and patients navigating their medical journey with this medication.

© 2011 Journal of Case Reports
Last updated on Jan 19, 2025